Role of 5-hydroxytryptamine type 3 receptors in aerobic exercise-induced improvement of memory and hippocampal synaptic plasticity.

Type 2 diabetes (T2D) represents a pervasive chronic health issue globally, characterized primarily by insulin resistance and impaired insulin secretion. Recent studies have demonstrated that chronic subclinical inflammation constitutes a significant contribution to the pathogenesis of T2D. Adipocytes, for instance, contribute to elevated levels of C-reactive protein (CRP) through the secretion of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6). CRP is implicated in the pathophysiology of the vascular system and the development of metabolic syndrome by influencing physiological processes, including endothelial function, vasodilation, and vascular remodeling. These findings underscore the potential benefits of further investigating the interplay between inflammation and T2D. With the progression of molecular biology, immune-targeted therapies have shown significant efficacy in the treatment of tumors and autoimmune diseases. Compared to traditional immunosuppressive drugs, immune-targeted agents provide the advantages of enhanced efficacy and diminished toxicity. Immune-targeted therapies are categorized into 5 categories based on the specific antibody targets: TNF inhibitors, IL inhibitors, integrin inhibitors, B cell depletion/inhibition agents, and T cell depletion agents. IL-6 is a pleiotropic cytokine involved in the regulation of a wide array of physiological and pathological processes, notably contributing to inflammation, immune response, metabolism, among other functions. Tocilizumab (TCZ), a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor, inhibits the IL-6 mediated inflammatory cascade implicated in the pathogenesis of rheumatoid arthritis (RA). Clinical trials have demonstrated that TCZ monotherapy exhibits superior efficacy compared to monotherapy with TNF-α inhibitors (TNFi) and methotrexate monotherapy. Exploring the relationship between immune-targeted therapies and T2D, is of significant importance for the development of novel therapeutic agents and the optimization of clinical treatment strategies. Drug-targeted Mendelian randomization (MR) has been widely employed to identify therapeutic agents for a range of diseases. There is considerable interest in exploring the effects of lipid-lowering drugs on non-cardiovascular diseases. In contrast to traditional 2-sample MR, drug-targeted MR focuses exposure factors on specific target genes, improving the accuracy of confounding variable elimination. However, the causal relationship between IL6 inhibitors and T2D remains unresolved. It is also crucial to acknowledge that T2D is associated with changes in various metabolite levels, which can serve as indicators of physiological alterations. Consequently, this study considered T2D as a mediating factor to explore whether cerebrospinal fluid (CSF) metabolites were influenced in patients with T2D who were treated with IL-6 receptor inhibitors. This research enhanced our understanding of the interplay between IL-6 receptor inhibitors, T2D and CSF metabolites, offering valuable insights for clinicians.